Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Sanofi-Aventis Bristol-Myers Squibb |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00265967 |
Study objectives:
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Irbesartan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Missed Dose Effect of Irbesartan in Hypertensive Patients and Cardiovascular Risk Profile Monitoring Under Irbesartan Treatment |
Enrollment: | 88 |
Study Start Date: | September 2005 |
Primary Completion Date: | February 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Irbesartan
|
Drug: Irbesartan
Irbesartan 150-300 mg/d for 8 weeks
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Premenopausal women having at least one of the following conditions,
Having renal and/or hepatic failure together with the following laboratory criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Responsible Party: | sanofi-aventis ( Medical Affairs Study Director ) |
Study ID Numbers: | L_9917 |
Study First Received: | December 14, 2005 |
Last Updated: | September 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00265967 |
Health Authority: | Turkey: Ministry of Health |
Irbesartan Vascular Diseases Angiotensin II Hypertension |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Therapeutic Uses Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |